# BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

> **NCT01624493** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Hoosier Cancer Research Network**

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** BNC105P

## Key facts

- **NCT ID:** NCT01624493
- **Lead sponsor:** Hoosier Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-10
- **Primary completion:** 2014-07
- **Final completion:** 2014-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Phase I was conducted Australia. Phase II not conducted and no US pts enrolled.
- **Last updated:** 2015-12-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624493, "BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01624493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*